Accessibility Menu
Ezz Life Science logo

Ezz Life Science(ASX) EZZ

Market CapA$22.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-55%
5 Year+27%
1 Year-80%
1 Month+4%
A$0.47
+0.00%
+0.00Today
Ezz Life Science last closing stock price
MetricPriceDate
Last closeAUD 0.472026-08-13
Ezz Life Science stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.05%AUD 0.482026-08-06
1 month+4.44%AUD 0.452026-07-14
3 month-25.4%AUD 0.632026-05-15
Year to date-66.67%AUD 1.412025-12-31
1 year-79.75%AUD 2.322025-08-13
3 year-18.31%AUD 0.582023-08-14
5 year+27.01%AUD 0.372021-08-13
Since inception-55.11%AUD 1.052021-03-03

Ezz Life Science Financials at a Glance

Market Cap

A$22.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$136.44M

Net Income (TTM)

A$11.91M

EPS (TTM)

A$0.06

P/E Ratio

7.67

Dividend

A$0.02

Beta (Volatility)

0.12 (Low)

Price

A$0.47

Volume

0

Open

A$0.47

Previous Close

A$0.47

Daily Range

A$0.47 - A$0.47

52-Week Range

A$0.36 - A$3.38

Estimated Earnings Date

Sep 2, 2026

EZZ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ezz Life Science

EZZ Life Science Holdings Limited is an Australian biotechnology company specializing in skincare and consumer health products. The company operates in Australia, New Zealand, Mainland China, and other international markets, offering a diverse range of products under its EZZ and EAORON brands.

Products and Services
  • Skincare products under the EAORON brand
  • Vitamins, dietary supplements, and sports nutrition products
  • Traditional herbal remedies and paediatric health solutions
Growth Outlook
  • Revenue of AUD 24.82 million in the latest quarter indicates strong market demand
  • Gross profit margin of 62.63% reflects effective cost management
  • Expansion into international markets is expected to drive future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 109.5 million shows consistent performance
  • Net income of AUD 3.53 million in the last quarter demonstrates profitability
  • Dividend yield of 8.60% offers attractive returns for investors
EZZ Life Science Holdings Limited has established a solid foundation in the biotechnology sector, focusing on innovative health and skincare solutions. The company's diverse product offerings cater to a wide range of consumer needs, positioning it well for future growth. Recent financial performance highlights a strong revenue stream and profitability, making it an appealing option for potential investors. The company's strategic expansion into international markets further enhances its growth prospects, while a robust gross profit margin indicates effective operational management. With a competitive dividend yield, EZZ Life Science Holdings Limited presents an interesting opportunity in the biotechnology industry.
AI Generated • Aug 3, 2026

Industry

Personal Products

CEO

Qi Zhou Qin

Headquarters

Lidcombe, NSW 2141, AU

EZZ Financials

Key Financial Metrics (TTM)

Gross Margin

68.32%

Operating Margin

12.95%

Net Income Margin

4.71%

Return on Equity

10.35%

Return on Capital

34.98%

Return on Assets

8.87%

Earnings Yield

13.04%

Dividend Yield

4.26%

Payout Ratio

63.89%

Stock Overview

Market Cap

A$22.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

47.04M

Volume

0

Avg. Volume

20.43K

Financials (TTM)

Gross Profit

A$100.00M

Operating Income

A$21.96M

EBITDA

A$19.22M

Operating Cash Flow

A$5.35M

Capital Expenditure

-A$640.29K

Free Cash Flow

A$4.71M

Cash & ST Invst.

A$13.47M

Total Debt

A$123.86K

Ezz Life Science Performance Analysis

Ezz Life Science annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 15,022,026N/A
20232023-06-30AUD 37,143,330147.3%
20242024-06-30AUD 66,443,37178.9%
20252025-06-30AUD 66,873,6910.6%
Ezz Life Science sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30106.2%
Q22024-12-31-32.3%
Q42025-06-3020.8%
Q22025-12-31-32.2%
Ezz Life Science annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD 0.03N/A
20232023-06-30AUD 0.09175.1%
20242024-06-30AUD 0.1690.1%
20252025-06-30AUD 0.15-10.0%
Ezz Life Science sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30385.1%
Q22024-12-31-45.7%
Q42025-06-305.9%
Q22025-12-31-118.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$24.82M

+14.4%

Gross Profit

A$15.54M

+6.8%

Gross Margin

62.63%

N/A

Market Cap

A$22.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.01M

N/A

Employees

11

N/A

Net Income

-A$641.30K

-156.1%

EBITDA

A$137.43K

-92.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$13.47M

+6.8%

Total Debt

A$123.86K

-59.3%

Accounts Receivable

A$7.07M

+115.8%

Inventory

A$3.73M

+139.2%

Long Term Debt

A$0.00

N/A

Short Term Debt

A$123.86K

-59.3%

Return on Assets

8.87%

N/A

Return on Invested Capital

28.60%

N/A

Free Cash Flow

-A$5.52M

-1272.8%

Operating Cash Flow

-A$5.50M

-1549.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PCK.AXPainChek Limited
A$0.10-5.71%
IMU.AXImugene Limited
A$0.08+1.22%
BIO.AXBiome Australia Limited
A$0.30+3.51%
ALA.AXArovella Therapeutics Limited
A$0.06+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.56+0.02%
CDECoeur Mining
$18.45-0.02%
TAT&T
$24.58+0.01%
SMRNuScale Power
$9.85+0.03%

Questions About EZZ

What is the current price of Ezz Life Science?

Ezz Life Science is trading at A$0.47 per share.

What is the 52-week range for Ezz Life Science?

Over the past 52 weeks, Ezz Life Science has traded between A$0.36 and A$3.38.

How much debt does Ezz Life Science have?

As of the most recent reporting period, Ezz Life Science reported total debt of A$304.49K.

How much cash does Ezz Life Science have on hand?

Ezz Life Science reported A$20.85M in cash and cash equivalents in its most recent financial results.

What is Ezz Life Science’s dividend yield?

Ezz Life Science currently has a dividend yield of 4.26%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.